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Дослідження протимікробної дії модельних зразків потенційного лікарського засобу у різних фіксованих 
комбінаціях та доведення специфічної антимікотичної активності модельних зразків нового, комбіно-
ваного, потенційного лікарського засобу та препарату, обраного в якості референтного «Нео-
Пенотран®» (Екселтіс Хелске С.Л., Іспанія).  
Метою дослідження було встановлення чутливості in vitro ізолятів Candida spp. до нового комбіновано-
го лікарського засобу, що містить в своєму складі субстанцію з антимікотичною дією для лікування ва-
гінального кандидозу.  
Матеріали та методи. Для доведення активності та визначення чутливості використовували ізоляти 
Candida albicans (ATCC 10231) та Candida albicans (клінічний ізолят) з матеріалу, урогенітальних шля-
хів від жінок з діагнозом кандидоз. 
Вивчення протимікробної дії проводили за методом серійних розведень в триптиказо-соєвому бульйоні, 
що дозволив забезпечити рівномірний розподіл препарату в поживному середовищі при контакті з па-
тогенними штамами, а подальший пересів на чашки Петрі на Сабуро агар - найбільш точну оцінку ре-
зультатів. 
Результати вивчення антимікотичної активності 7 модельних зразків, свідчать про наявність антимі-
котичної активності лише у 3 модельних зразках по відношенню як до еталонного штаму Candida albi-
cans ATCC 10231, так і клінічного штаму Candida albicans.  
Висновки. Отримані результати досліджень свідчать про наявність виразного антимікотичного ефе-
кту in vitro нового потенційного комбінованого лікарського засобу відносно патогенних тест-штамів: 
Candida albicans ATCC 10231, Candida albicans (клінічний ізолят), який не поступається обраному рефе-
рентному препарату. Встановлено мінімільну інгібуючу концентрацію досліджуваного препарату in 
vitro відносно патогенних тест-штамів: Candida albicans ATCC 10231, Candida albicans (клінічний ізо-
лят). Проведене дослідження різних комбінацій та концентрацій комбінованого препарату дозволило 
виключити наявність негативної взаємодії між компонентами експериментального зразку та виділити 
найбільш перспективний та ефективний зразок для подальших експериментальних досліджень комбіна-
цій антимікотиків для інтравагінального застосування 
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1. Introduction 
Diseases with infectious etiology of the reproduc-
tive system of a woman are one of the most important 
medical and social problems in the structure of which the 
defeat of fungal nature play an essential role. However, 
there is practically no statistically reliable information on 
the prevalence of vaginal candidiasis (VC), since in most 
cases the disease is not isolated from other dysbiotic 
processes that are often recorded in women's vaginal 
biotope. The frequency of VC in the last five years has 
increased by 2 times and ranged from 26 to 45 % in the 
structure of the infectious pathology of the gynecological 
profile [1]. 
 
2. Formulation of the problem in a general 
way, the relevance of the theme and its connection 
with important scientific and practical issues 
Inflammatory diseases of the pelvic organs occupy 
one of the leading places in the structure of gynecological 
pathology and are detected in 60–65 % of all gynecologi-
cal patients. Inadequate treatment of these diseases leads 
to a chronic process, forming the basis of pathological 
conditions, which subsequently violate the fertile function 
of women. 
To date, gynecological practice has widely used 
vaginal suppositories containing various active pharma-
ceutical ingredients (APIs). The range of multicomponent 
suppositories is only 11 % of the total number of vaginal 
suppositories registered in Ukraine. Based on the forego-
ing, it can be argued that the importance of creating a 
vaginal suppository of multi-directional action for the 
treatment of VC. 
 
3. Analysis of recent studies and publications in 
which a solution of the problem are described and to 
which the author refers 
The main agents of these infections are fungi of 
the Candida genus [2]. The prevalence of Candida albi-
cans in females of reproductive age is 83.7–86 %, non-
albicans species – 14–16.3 % without a marked tendency 
to increase or decrease [3]. Often, vaginitis occurs due to 
the combination of several factors, for example, bacterial 
and fungal nature, accounting for 10 to 30 % of all cases 
of infectious diseases in gynecology. The result of the 
mutual influence of pathogens is difficult to predict, but 
in most cases, the clinical picture is changing, which 
complicates the diagnosis and choice of adequate therapy 
[4]. In addition, to date no clear guidelines that allow 
evaluating the role allocated from the vaginal contents of 
fungi of the Candida genus, colonization of mucous 
membranes which in healthy people varies from 15 to  
40 % and may increase to 80 % against the pathological 
process in prolonged hospitalization [5]. Being present in 
biocenosis, they interact with other types of conditionally 
pathogenic microorganisms and representatives of nor-
mal flora, changing the factors of persistence and viru-
lence of the latter [6]. 
In microbial associations between different types 
of pathogens appear ambiguous relationship that could 
materially affect the nature of the infection [7], and re-
quires the appointment of drugs that would have a com-
plex pharmacotherapeutic activity. 
 
4. The field of research considering the general 
problem, which is described in the article  
Among the drugs for the treatment of candidiasis 
vulvovaginitis the most commonly used derivatives of 
azoles - metronidazole, tinidazole, clotrimazole, keto-
conazole, miconazole and others. Compared with known 
antibiotics (nystatin, amphotericin, natamycin, etc.), 
these drugs provide more reliable and safer treatment for 
women with inflammatory lesions caused by fungal, 
protozoal and other infections [11]. Therefore, one of the 
components of the combined drug were selected imidaz-
oles (metronidazole and clotrimazole), which until now 
remain the drugs of the first line of treatment of VC 
complicated by bacterial infection. 
High permeability of active substances to the in-
accessible excretory ducts of the glands, as well as crypt, 
lacunae with inflammation, along with the ease of admin-
istration without the help of medical personnel, indicate 
the promise of the investigated potential medicines in the 
form of suppositories. 
 
5. Formulation of goals (tasks) of article 
Aim of the research – to establish the sensitivity 
of in vitro Candida spp. isolates to a new combined drug 
containing a substance with an antimycotic effect for the 
treatment of vaginal candidiasis. 
 
6. Presentation of the main research material 
(methods and objects) with the justification of the 
results 
Materials and methods. Experimental studies 
were conducted in accordance with "Methodological 
recommendations for the preclinical study of potential 
drugs with antimicrobial activity" [8, 9] and the meth-
odological recommendations "Determination of microor-
ganism sensitivity to antibacterial preparations", ap-
proved by the Order of the Ministry of Health of Ukraine 
dated April 5, 2007, No. 167. 
Candida albicans (ATCC 10231) derived from the 
UCM (Ukrainian Collection of Microorganisms, Institute 
of Microbiology and Virology of the National Academy 
of Sciences of Ukraine) and Candida albicans (clinical 
isolate) from the material, urogenital tracts from women 
with a diagnosis of candidiasis obtained in Institute of 
urology, NAMS of Ukraine. 
Identification of Candida species was performed 
by investigating the structure of colonies in a chromo-
genic medium (ChromID ™ Candida, Biomere, France) 
after 24–48 hours of incubation at 35 °C using a standard 
system (API® Candida, Biomerej, France). To ensure 
purity and viability, frozen cells of yeast isolates were 
sown on Saburi agar with dextrose, chloramphenicol and 
incubated at 35 °C for 24 hours. This procedure was 
repeated twice before testing for sensitivity to the inves-
tigated pharmacological agents. 
The study of antimicrobial activity was carried out 
by the method of serial dilutions in trypticase-soybean 
broth. The chosen approach allows ensuring the uniform 
distribution of the drug in the nutrient medium in contact 
with pathogenic strains, and the subsequent transfer to 
Petri dishes on Sabouraud agar - the most accurate evalu-
ation of the results. 
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The study of the antimicrobial effect of model spec-
imens of a potential drug in various fixed combinations and 
the demonstration of specific antimycotic activity was per-
formed using model samples of a new, combined, potential 
drug and drug selected as a reference "Neo-Penotran®" 
(Exeltis Healthcare S.L., Spain) (Table 1). 
 
Table 1 
Composition of the studied samples of medicinal 
products 
Sample 
No. Composition (API) 
AFI content in g 
per 1 suppository 
1 Base + auxiliary substances up to 4.00 
2. Ibuprofen 0.08 
3. Metronidazole 0.10 
4. Clotrimazole 0.40 
5. Ibuprofen Metronidazole 
0.08 
0.10 
6. Ibuprofen Clotrimazole 
0.08 
0.40 
7. 
Ibuprofen 
Clotrimazole 
Metronidazole 
0.08 
0.40 
0.10 
8. 
Neo-Penotran® 
Miconazole 
Metronidazole 
(comparison drug) 
0.10 
0.50 
 
The studies began with the receipt of Candida al-
bicans daily cultures, preparation of the initial and work-
ing suspensions of Candida albicans, and the aliquots 
hanging from the experimental and control suspensions 
to determine the minimum fungicidal concentrations 
(MFCs) of the preparations were carried out on a semi-
conductive medium of trypticase-soybean broth (TSB) in 
a test tube. Subsequently, he was transferred to Petri 
dishes with a solid nutrient medium - Sabouraud agar. 
Parallel preparation of the initial solutions of 
model specimens of the new combined drug and the 
reference preparation Neo-Penotran® (Exeltis 
Healthcare S.L., Spain), obtained by melting the sup-
pository in a water bath with the addition of 40 ml of 
TSB medium. The initial concentration thus obtained 
was ¼ suppository in 10 ml medium, which is 10 mg/ml 
clotrimazole. For further studies, the concentration of 
drugs in the initial solution was reduced by half com-
pared with the previous one, namely: 1/8, 1/16, 1/32, 
1/64, 1/128 and 1/256 suppository corresponding to the 
concentration of 5, 2,5 , 1.25, 0.63, 0.315, 0.16, 0.08, 
0.04 mg / ml of clotrimazole, respectively. For this pur-
pose, 5 ml of the initial solutions were mixed with a 
similar volume of the TBC nutrient medium. A similar 
way was achieved by doubling the concentrations of the 
initial solutions for the study of activity against Candida 
albicans. Subsequently, for each type of Candida spp., a 
number of 8–10 samples were prepared, in which the 
appropriate test was carried out, strains of microorgan-
isms of 0.1 ml. Concentration of culture in test tubes with 
drugs and control of culture was about 5×106 in 1 ml.  
The inoculations were incubated for 2 days at  
37.5 °C. After the incubation was complete, from each 
test tube, a loop was driven onto cubes with Sabouraud 
agar medium on a solid nutrient medium. Cultures were 
incubated for 2 days at 37.5 °C. In this case, the titers of 
Candida albicans strains were 5×107 CFU in 0.1 ml, 
which corresponded to the requirements of the experi-
ment in accordance with similar studies. 
In experimental samples, working concentrations, 
from which the study of the effect of a new combined 
drug with antimycotic and anti-inflammatory activity on 
test microorganisms, was 1/2 of suppository (20 mg/ml 
of clotrimazole), the final investigated concentration - 
1/1024 suppositories (0.04 mg/ml clotrimazole). The 
content of clotrimazole in one suppository (in the sam-
ples of sample No. 1 to 7 with a total weight of  
4.0 grams) was 400 mg. Based on the above, the concen-
tration range of clotrimazole in experimental tubes with 
the specified preparation for Candida albicans was in the 
range from 20.00–0.04 mg / ml. 
The range of the test concentrations of the anti-
mycotic ingredient of the comparator product ranged 
from 5 mg/ml miconazole to 0.01 mg/ml of miconazole. 
All experiments were carried out in triple repeti-
tions according to the requirements of pre-clinical studies 
in vitro. The results were recorded visually, by compar-
ing the intensity of growth of test cultures on Petri dishes 
with sampled drug with growth culture in control.  
Results and their discussion.  
On the basis of previous studies conducted at the 
Department of Pharmaceutical Technology and Bio-
pharmacy of the National Medical Academy of Post-
graduate Education named after P.L. Shupik under the 
direction of Professor L. L. Davtyan, a potential medici-
nal product for intravaginal administration containing 
three active substances was developed: metronidazole , 
clotrimazole and ibuprofen. The chosen dosage form 
should provide immediate action at the center of the 
inflammatory process, which will potentially contribute 
to a significant reduction in the frequency of undesirable 
side effects. 
Results of the study of antimycotic activity of 
model specimens number 4 containing one active ingre-
dient, clotrimazole, are given in table. 2, indicate the 
presence of antimycotic activity in this sample in relation 
to both the reference strain Candida albicans ATCC 
10231 and the clinical strain Candida albicans. 
Sample No. 4 (base + clotrimazole) was found to 
have a distinct fungistatic and fungicidal activity against 
the studied fungi of the Candida genus, due to the inhibi-
tion of the ergosterol biosynthesis which regulates the 
permeability of the cell wall of the microorganisms. The 
inhibition of the Candida albicans strain ATCC 10231 
was observed at the dilution of the drug to 1/128 supposi-
tories, the MIC (minimum inhibitory concentration) was 
0.315 mg/ml clotrimazole, for the clinical strain Candida 
albicans dilution was 1/32 (MIC – 1.25 mg/ml). Compar-
ing the activity of sample No. 4 to reference and clinical 
isolates, the MIC was higher for the clinical strain, due to 
the formation of resistance of the microorganisms, which 
developed a certain set of mechanisms of resistance to 
the action of antifungal drugs. 
Subsequent experimental studies were conducted 
to confirm the absence of a negative pharmacological 
interaction in the two-component Sample No. 6 (clotri-
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mazole + ibuprofen) and the three-component Sample 
No.7 (clotrimazole + metronidazole + ibuprofen), which 
could subsequently affect the antimycotic activity of the 
drug. Listed in tab. 3, 4 results of the analysis of in vitro 
antifungal activity of samples No. 6 and 7 containing 
clotrimazole in a concentration from 20 to 0.04 mg/ml in 
relation to pathogenic test strains: Candida albicans 
ATCC 10231, Candida albicans (clin. strain) (Table 3) 
demonstrated the presence of comparable antimycotic 
activity with sample No. 4 (clotrimazole + base), sug-
gesting the absence of pharmacodynamic interaction 
(synergism or antagonism) between clotrimazole, metro-
nidazole and ibuprofen. 
Thus, it was found that Samples No. 6 and No. 7 
had a pronounced antimycotic activity in the Candida 
species of the studied fungi only due to the presence of 
clotrimazole in the APIs with fungicidal and fungistatic 
activity. Inhibition of the Candida albicans strain ATCC 
10231 was observed at dilution of the preparation to 
1/128 suppository (MIC clotrimazole - 0.315 mg/ml), for 
the clinical strain Candida albicans dilution was 1/32 
(MIC clotrimazole – 1.25 mg/ml). The maximum anti-
mycotic effect against Candida albicans ATCC 10231 
was achieved at dilution to 1/16 suppository (based on 
the concentration of clotrimazole in the sample –  
2.5 mg/ml), and for the clinical strain Candida albicans – 
1/2 suppository (in terms of concentration of clotrima-
zole in the sample – 10 mg/ml).  
Confirmation of absence of antifungal activity in 
vitro of samples No. 1, No. 2, No. 3 and No. 5, which do 
not contain APIs containing an expressive antifungal 
activity, for pathogenic test strains: Candida albicans 
ATCC 10231, Candida albicans (clinical strain) shown in 
Table 5. 
The results of the analysis of the antifungal activi-
ty of the comparison drug "NEO-PENOTRAN®" con-
taining miconazole in a concentration from 5 to  
0.01 mg/ml in vitro for pathogenic test strains: Candida 
albicans ATCC 10231, Candida albicans (clinical strain) 
are given in Table 6.  
 
Table 2 
Antimycotic activity of Sample No. 4 in relation to Candida albicans (ATCC 10231 and clinical strain) 
No. 
study 
Concentration of the active ingredient - clotrima-
zole in mg/ml (dilution of the preparation supp/10 
ml of the medium) 
Candida albicans ATCC 
10231 
Candida albicans clin. 
strain 
І 
repeat 
ІІ 
repeat 
ІІІ 
repeat 
І 
repeat 
ІІ 
repeat 
ІІІ 
repeat 
1. 20 (1/2) - - - - - - - - - - - - - - - - - - 
2. 10 (1/4) - - - - - - - - - - - + - - + - - + 
3. 5 (1/8) - - - - - - - - - - - + - - + - - + 
4. 2.5 (1/16) - - - - - - - - - - + + - - + - - + 
5. 1.25 (1/32) - - + - - - - - - - + + - + + - + + 
6. 0.63 (1/64) - - + - - + - - + + + + + + + + + + 
7. 0.315 (1/128) - + + - + + - + + + + + + + + + + + 
8. 0.16 (1/256) + + + + + + + + + + + + + + + + + + 
9. 0.08 (1/512) +++ +++ +++ + + + + + + + + + 
10. 0.04 (1/1024) +++ +++ +++ + + + + + + + + + 
11. Cultural control +++ +++ +++ + + + + + + + + + 
Notes: +++ – 100 % intensive growth of microorganisms, similar to culture growth without preparation; - ++ – growth of microor-
ganisms by 30 % suppressed relative to the growth of culture without the preparation; - - + – growth of microorganisms by 60 % 
suppressed relative to the growth of culture without the preparation; - - - – complete inhibition of growth of microorganisms 
 
 
Table 3 
Antimycotic activity of Sample No. 6 in relation to Candida albicans (ATCC 10231 and clinical strain) 
No. 
study 
Dilution of the preparation supp/10 ml of the 
medium (mg/ml of the active ingredient – 
clotrimazole) 
Candida albicans ATCC 
10231 
Candida albicans clin. 
strain 
І repeat ІІ 
repeat 
ІІІ 
repeat 
І 
repeat 
ІІ 
repeat 
ІІІ 
repeat 
1. 1/2 (20) - - - - - - - - - - - - - - - - - - 
2. 1/4 (10) - - - - - - - - - - - + - - + - - + 
3. 1/8 (5) - - - - - - - - - - - + - - + - - + 
4. 1/16 (2.5) - - - - - - - - - - + + - - + - - + 
5. 1/32 (1.25) - - - - - - - - - - + + - + + - + + 
6. 1/64 (0.63) - - + - - + - - + + + + + + + + + + 
7. 1/128(0.315) - + + - + + - + + + + + + + + + + + 
8. 1/256 (0.16) + + + + + + + + + + + + + + + + + + 
9. 1/512 (0.08) + + + + + + + + + + + + + + + + + + 
10. 1/1024 (0.04) + + + + + + + + + + + + + + + + + + 
11. Cultural control + + + + + + + + + + + + + + + + + + 
 
 
Scientific Journal «ScienceRise: Pharmaceutical Science»                                                                    №1(11)2018 
 
51 
Table 4 
Antimycotic activity of Sample No. 7 in relation to Candida albicans (ATCC 10231 and clinical strain) 
No. 
study 
Dilution of the preparation supp/10 ml of the 
medium (mg/ml of the active ingredient – 
clotrimazole) 
Candida albicans ATCC 
10231 
Candida albicans clin. 
strain 
І repeat ІІ 
repeat 
ІІІ 
repeat 
І 
repeat 
ІІ 
repeat 
ІІІ 
repeat 
1. 1/2 (20) - - - - - - - - - - - - - - - - - - 
2. 1/4 (10) - - - - - - - - - - - + - - + - - + 
3. 1/8 (5) - - - - - - - - - - - + - - + - - + 
4. 1/16 (2.5) - - - - - - - - - - + + - - + - - + 
5. 1/32 (1.25) - - - - - - - - - - + + - + + - + + 
6. 1/64 (0.63) - - + - - + - - + + + + + + + + + + 
7. 1/128(0.315) - + + - + + - + + + + + + + + + + + 
8. 1/256 (0.16) + + + + + + + + + + + + + + + + + + 
9. 1/512 (0.08) + + + + + + + + + + + + + + + + + + 
10. 1/1024 (0.04) + + + + + + + + + + + + + + + + + + 
11. Cultural control + + + + + + + + + + + + + + + + + + 
 
Table 5 
Antimycotic activity of Samples No. 1, No. 2, No. 3, and No. 5 in relation to both Candida albicans (ATCC 
10231 and clinical strain) 
No. 
study 
Dilution of the 
preparation 
supp/10 ml of the 
medium 
Candida albicans ATCC 10231 Candida albicans clin. strain 
Sample 
No. 1 
Sample 
No. 2 
Sample 
No. 3 
Sample 
No. 5 
Sample 
No. 1 
Sample 
No. 2 
Sample 
No. 3 
Sample 
No.5 
1. 1/2 + + + + + + + + + + + + + + + + + + + + + + + + 
2. 1/4 + + + + + + + + + + + + + + + + + + + + + + + + 
3. 1/8  + + + + + + + + +  + + + + + + + + + 
4. 1/16  + + + + + + + + +  + + + + + + + + + 
5. Cultural control + + + + + + + + + + + + + + + + + + + + + + + + 
 
 
Table 6 
Research of the antimycotic activity of the reference preparation "NEO-PENOTRAN®" in relation to Candida albicans 
(ATCC 10231 and clinical strain) 
No. 
study 
Dilution of the preparation supp/10 ml of the 
medium (mg/ml of the active ingredient – 
miconazole) 
Candida albicans ATCC 
10231 
Candida albicans clin. 
strain 
І re-
peat 
ІІ 
repeat 
ІІІ 
repeat 
І 
repeat 
ІІ 
repeat 
ІІІ 
repeat 
1. 1/2 (5) - - - - - - - - - - - + - - + - - + 
2. 1/4 (2.5) - - - - - - - - - - - + - - + - - + 
3. 1/8 (1.25) - - - - - - - - - - - + - - + - - + 
4. 1/16 (0.63) - - - - - - - - - - + + - + + - + + 
5. 1/32 (0.315) - - - - - - - - - - + + - + + - + + 
6. 1/64 (0.16) - - - - - - - - - + + + + + + + + + 
7. 1/128 (0.08) - - - - - - - - - + + + + + + + + + 
8. 1/256 (0.04) - + + - + + - + + + + + + + + + + + 
9. 1/512 (0.02) +++ +++ +++ + + + + + + + + + 
10. 1/1024 (0.01) +++ +++ +++ + + + + + + + + + 
11. Cultural control +++ +++ +++ + + + + + + + + + 
  
The conducted studies have established (table 6) 
that the reference preparation "NEO-PENOTRAN®" with 
active ingredient miconazole has been shown to have a 
pronounced antimycotic activity against Candida albicans 
(ATCC 10231). A moderate antifungal effect is recorded 
at a concentration of 0.04 mg/ml of miconazole, corre-
sponding to 1/256 suppositories diluted in 10 ml of medi-
um. Less distinctive activity is shown by this sample in 
relation to the clinical strain Candida albicans. The anti-
fungal effect is recorded at a concentration of 0.315 mg/ml 
of miconazole, which is 8 times higher than the MIC of 
miconazole relative to the museum strain (Fig. 1), which 
can be explained by the presence of a large number of 
resistant microorganisms resistant to miconazole. 
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Fig. 1. Result of comparison of antimicrobial activity 
 
The above results showed that the antimycotic 
activity of the study drug is not inferior to the activity 
of the selected reference preparation, and in relation 
to Candida albicans (clinical strain) is more pro-
nounced, which is explained by the resistance of the 
strains to many antimycotic drugs with intravaginal 
administration. 
However, the activity was lower in relation to 
Candida albicans ATCC 10231, which can be justified by 
different MICs of clotrimazole and miconazole, as well 
as different concentrations of APIs in suppositories.  
 
7. Conclusions from the conducted research 
and prospects for further development of this field 
1. The results of the studies indicate that there is a 
clear in vitro antimycotic effect of the new potential com-
bined drug relative to pathogenic test strains: Candida albi-
cans ATCC 10231, Candida albicans (clinical isolate). 
2. A comparative study of the antimycotic activity 
of the experimental samples of the new combined drug 
and the referent drug showed an antimycotic effect in the 
investigated concentrations. 
3. It has been found that the MIC of the test drug 
in vitro with regard to pathogenic test strains: Candida 
albicans ATCC 10231, Candida albicans (clinical iso-
late) is 0.315 mg/ml and 1.25 mg/ml clotrimazole, re-
spectively. 
4. The conducted microbiological study of various 
combinations and concentrations of the combined prepa-
ration allowed to exclude the presence of negative inter-
action between the components of the experimental sam-
ple and to allocate the most promising and effective sam-
ple for further experimental studies of combinations of 
antimycotics for intravaginal use. 
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